Literature DB >> 15974594

Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.

David C M Chan1, Hongning Fu, Ronald A Forsch, Sherry F Queener, Andre Rosowsky.   

Abstract

As part of a search for dihydrofolate reductase (DHFR) inhibitors combining the high potency of piritrexim (PTX) with the high antiparasitic vs mammalian selectivity of trimethoprim (TMP), the heretofore undescribed 2,4-diamino-6-(2',5'-disubstituted benzyl)pyrido[2,3-d]pyrimidines 6-14 with O-(omega-carboxyalkyl) or omega-carboxy-1-alkynyl groups on the benzyl moiety were synthesized and tested against Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium DHFR vs rat DHFR. Three N-(2,4-diaminopteridin-6-yl)methyl)-2'-(omega-carboxy-1-alkynyl)dibenz[b,f]azepines (19-21) were also synthesized and tested. The pyridopyrimidine with the best combination of potency and selectivity was 2,4-diamino-5-methyl-6-[2'-(5-carboxy-1-butynyl)-5'-methoxy]benzyl]pyrimidine (13), with an IC(50) value of 0.65 nM against P. carinii DHFR, 0.57 nM against M. avium DHFR, and 55 nM against rat DHFR. The potency of 13 against P. carinii DHFR was 20-fold greater than that of PTX (IC(50) = 13 nM), and its selectivity index (SI) relative to rat DHFR was 85, whereas PTX was nonselective. The activity of 13 against P. carinii DHFR was 20 000 times greater than that of TMP, with an SI of 96, whereas that of TMP was only 14. However 13 was no more potent than PTX against M. avium DHFR, and its SI was no better than that of TMP. Molecular modeling dynamics studies using compounds 10 and 13 indicated a slight binding preference for the latter, in qualitative agreement with the IC(50) data. Among the pteridines, the most potent against P. carinii DHFR and M. avium DHFR was the 2'-(5-carboxy-1-butynyl)dibenz[b,f]azepinyl derivative 20 (IC(50) = 2.9 nM), whereas the most selective was the 2'-(5-carboxy-1-pentynyl) analogue 21, with SI values of >100 against both P. carinii and M. avium DHFR relative to rat DHFR. The final compound, 2,4-diamino-5-[3'-(4-carboxy-1-butynyl)-4'-bromo-5'-methoxybenzyl]pyrimidine (22), was both potent and selective against M. avium DHFR (IC(50) = 0.47 nM, SI = 1300) but was not potent or selective against either P. carinii or T. gondii DHFR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15974594     DOI: 10.1021/jm0581718

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Structural analysis of human dihydrofolate reductase as a binary complex with the potent and selective inhibitor 2,4-diamino-6-{2'-O-(3-carboxypropyl)oxydibenz[b,f]-azepin-5-yl}methylpteridine reveals an unusual binding mode.

Authors:  Vivian Cody; Jim Pace; Jessica Nowak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-09-08

2.  Structural analysis of Pneumocystis carinii dihydrofolate reductase complexed with NADPH and 2,4-diamino-6-[2-(5-carboxypent-1-yn-1-yl)-5-methoxybenzyl]-5-methylpyrido[2,3-d]pyrimidine.

Authors:  Vivian Cody; Jim Pace; Elizabeth Stewart
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-03-28

Review 3.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

4.  Bacterial infection imaging with [18F]fluoropropyl-trimethoprim.

Authors:  Mark A Sellmyer; Iljung Lee; Catherine Hou; Chi-Chang Weng; Shihong Li; Brian P Lieberman; Chenbo Zeng; David A Mankoff; Robert H Mach
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

5.  Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase.

Authors:  Vivian Cody; Jim Pace; Jennifer Piraino; Sherry F Queener
Journal:  J Struct Biol       Date:  2011-06-13       Impact factor: 2.867

6.  Toward Broad Spectrum Dihydrofolate Reductase Inhibitors Targeting Trimethoprim Resistant Enzymes Identified in Clinical Isolates of Methicillin Resistant Staphylococcus aureus.

Authors:  Stephanie M Reeve; Debjani Si; Jolanta Krucinska; Yongzhao Yan; Kishore Viswanathan; Siyu Wang; Graham T Holt; Marcel S Frenkel; Adegoke A Ojewole; Alexavier Estrada; Sherry S Agabiti; Jeremy B Alverson; Nathan D Gibson; Nigel D Priestley; Andrew J Wiemer; Bruce R Donald; Dennis L Wright
Journal:  ACS Infect Dis       Date:  2019-10-15       Impact factor: 5.084

7.  Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5'-(ω-carboxyalkoxy)benzyl]pyrido[2,3-d]pyrimidine derivatives.

Authors:  Vivian Cody; Jim Pace
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-12-16

8.  LigMerge: a fast algorithm to generate models of novel potential ligands from sets of known binders.

Authors:  Steffen Lindert; Jacob D Durrant; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2012-06-27       Impact factor: 2.817

Review 9.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

10.  Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.

Authors:  Vivian Cody; Jim Pace; Andre Rosowsky
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.